Organ systems

ADA's William T. Cefalu, MD, to Testify on the Rising Cost of Insulin Before the Oversight and Investigations Subcommittee of the U.S. House of Representatives' Committee on Energy & Commerce on Tuesday, April 2

Retrieved on: 
Friday, March 29, 2019
Endocrine system, Organ systems, Medicine, RTT, Diabetes, Eli Lilly and Company, Diabetes mellitus, Prediabetes, Insulin

The ADA is steadfastly committed to continuing to work toward long-term solutions that ensure affordable access to insulin for all who need it.

Key Points: 
  • The ADA is steadfastly committed to continuing to work toward long-term solutions that ensure affordable access to insulin for all who need it.
  • Nearly half of the American adult population has diabetes or prediabetes, and more than 30 million adults and children are living with the disease.
  • For nearly 80 years, the ADA has driven discovery by funding research to treat, manage and prevent all types of diabetes, while working relentlessly for a cure.
  • To learn more or to get involved, call 1-800-DIABETES (1-800-342-2383) or visit us at diabetes.org .

Can-Fite Files Annual Report for the Year Ended December 31, 2018

Retrieved on: 
Friday, March 29, 2019
Health, Biotechnology, Pharmaceutical, Professional services, Finance, RTT, Medical specialties, Medicine, Organ systems, Psoriasis, Prostate cancer, Arthritis, Cancer

The annual report, which contains the Companys audited consolidated financial statements, can be accessed on the SECs website at http://www.sec.gov/ as well as via the Company's investor relations website at https://ir.canfite.com .

Key Points: 
  • The annual report, which contains the Companys audited consolidated financial statements, can be accessed on the SECs website at http://www.sec.gov/ as well as via the Company's investor relations website at https://ir.canfite.com .
  • The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.
  • Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
  • These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

Professor Clive Ballard Wins 2019 International Outstanding Achievement Award

Retrieved on: 
Friday, March 29, 2019
Clive Ballard, Dementia, Organ systems, Neurodegeneration, Branches of biology

TORONTO, March 29, 2019 /PRNewswire/ -- Professor Clive Ballard, Executive Dean of the University of Exeter Medical School, was presented with the 2019 Weston Brain Institute International Outstanding Achievement Award in Lisbon, Portugal.

Key Points: 
  • TORONTO, March 29, 2019 /PRNewswire/ -- Professor Clive Ballard, Executive Dean of the University of Exeter Medical School, was presented with the 2019 Weston Brain Institute International Outstanding Achievement Award in Lisbon, Portugal.
  • 2019 International Outstanding Achievement Award: Professor Clive Ballard
    Professor Clive Ballard is a world leader in dementia prevention and drug discovery, and an advocate for improved care for patients of neurodegenerative diseases of aging.Throughout his career, Professor Ballard has been the lead PI or co-PI on more than 30 clinical trials that evaluate various therapeutic interventions for neurodegenerative diseases of aging.
  • Clive Ballard comments "I am absolutely honoured and delighted to receive the extremely prestigious 2019 Weston Brain Institute International Outstanding Achievement Award.
  • "I'm delighted that Professor Ballard was named this year's recipient of the 2019 Weston Brain Institute International Outstanding Achievement award.

Professor Clive Ballard Wins 2019 International Outstanding Achievement Award

Retrieved on: 
Friday, March 29, 2019
Clive Ballard, Dementia, Organ systems, Neurodegeneration, Branches of biology

TORONTO, March 29, 2019 /PRNewswire/ -- Professor Clive Ballard, Executive Dean of the University of Exeter Medical School, was presented with the 2019 Weston Brain Institute International Outstanding Achievement Award in Lisbon, Portugal.

Key Points: 
  • TORONTO, March 29, 2019 /PRNewswire/ -- Professor Clive Ballard, Executive Dean of the University of Exeter Medical School, was presented with the 2019 Weston Brain Institute International Outstanding Achievement Award in Lisbon, Portugal.
  • 2019 International Outstanding Achievement Award: Professor Clive Ballard
    Professor Clive Ballard is a world leader in dementia prevention and drug discovery, and an advocate for improved care for patients of neurodegenerative diseases of aging.Throughout his career, Professor Ballard has been the lead PI or co-PI on more than 30 clinical trials that evaluate various therapeutic interventions for neurodegenerative diseases of aging.
  • Clive Ballard comments "I am absolutely honoured and delighted to receive the extremely prestigious 2019 Weston Brain Institute International Outstanding Achievement Award.
  • "I'm delighted that Professor Ballard was named this year's recipient of the 2019 Weston Brain Institute International Outstanding Achievement award.

Los Angeles Company Sets Out to "Turn On Your Hair" and Reinvent the Approach to Thinning Hair and Hair Loss at the Same Time

Retrieved on: 
Friday, March 29, 2019
Organ systems, Human hair, Hairdressing, Contents, Hair loss, RTT, Synergy, Hair, Integumentary system, Scalp

LOS ANGELES, March 29, 2019 /PRNewswire/ -- More Naturally, Inc. is set to shake up the 3.6 billion U.S. hair loss industry.

Key Points: 
  • LOS ANGELES, March 29, 2019 /PRNewswire/ -- More Naturally, Inc. is set to shake up the 3.6 billion U.S. hair loss industry.
  • More Naturally, Inc. believes it has found the answer in its new product: Hair & Scalp Synergy.
  • For centuries people have been looking for a way to reverse hair loss.
  • The combination of that product and the new Hair & Scalp Synergy creates a one-two punch of "fix and fire up."

Pharmascience Inc. launches (Pr)pms-PROGESTERONE 200 mg capsule indicated as an adjunct to postmenopausal estrogen replacement therapy

Retrieved on: 
Friday, March 29, 2019
Hormones, Endocrine system, Organ systems, Progestogens, Hepatotoxins, Prolactin releasers, Diketones, Pregnanes, Progesterone, Endometrial hyperplasia, Hormone replacement therapy, Estrogen

MONTREAL, March, 29, 2019 /CNW Telbec/ -Pharmascience Inc. is proud to launch Prpms-PROGESTERONE 200 mg (progestin), the only 200 mg progestin capsule available in Canada for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma.

Key Points: 
  • MONTREAL, March, 29, 2019 /CNW Telbec/ -Pharmascience Inc. is proud to launch Prpms-PROGESTERONE 200 mg (progestin), the only 200 mg progestin capsule available in Canada for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma.
  • Progesterone can be added to estrogen replacement therapy to avoid stimulation of the inner lining of the uterus and its cancer.
  • Each coated Prpms-PROGESTERONE capsule contains 200 mg of micronized progesterone in addition to several non-medicinal ingredients including sunflower oil.
  • 1
    Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal.

Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director

Retrieved on: 
Friday, March 29, 2019
Medicine, Medical specialties, Organ systems, Immune system, Cancer treatments, GD2, Glycolipids, Neuroblastoma, Chimeric antigen receptor T cell, T cell, TCB

GLASGOW, Scotland, March 29, 2019 /PRNewswire/ -- TC BioPharm (TCB), leaders in the development of tumor-targeting gamma delta T (GDT) cells, today announced that Professor John Anderson has been appointed as Scientific and Medical Director.

Key Points: 
  • GLASGOW, Scotland, March 29, 2019 /PRNewswire/ -- TC BioPharm (TCB), leaders in the development of tumor-targeting gamma delta T (GDT) cells, today announced that Professor John Anderson has been appointed as Scientific and Medical Director.
  • He is also the Chief Investigator of a Cancer Research UK sponsored trial of anti-GD2 CAR-T cells for neuroblastoma patients.
  • The company operates an integrated model, building all critical capabilities in-house, and Prof Anderson's arrival marks a significant addition to scientific and clinical capabilities.
  • Professor John Anderson, commented: "TCB have a unique portfolio of preclinical capabilities related to gamma delta CAR-T cells, which are now ripe for translation into the clinic.

Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director

Retrieved on: 
Friday, March 29, 2019
Medicine, Medical specialties, Organ systems, Immune system, Cancer treatments, GD2, Glycolipids, Neuroblastoma, Chimeric antigen receptor T cell, T cell, TCB

GLASGOW, Scotland, March 29, 2019 /PRNewswire/ -- TC BioPharm (TCB), leaders in the development of tumor-targeting gamma delta T (GDT) cells, today announced that Professor John Anderson has been appointed as Scientific and Medical Director.

Key Points: 
  • GLASGOW, Scotland, March 29, 2019 /PRNewswire/ -- TC BioPharm (TCB), leaders in the development of tumor-targeting gamma delta T (GDT) cells, today announced that Professor John Anderson has been appointed as Scientific and Medical Director.
  • He is also the Chief Investigator of a Cancer Research UK sponsored trial of anti-GD2 CAR-T cells for neuroblastoma patients.
  • The company operates an integrated model, building all critical capabilities in-house, and Prof Anderson's arrival marks a significant addition to scientific and clinical capabilities.
  • Professor John Anderson, commented: "TCB have a unique portfolio of preclinical capabilities related to gamma delta CAR-T cells, which are now ripe for translation into the clinic.

Aired by Ifeng.com, The “Super Tongue” Show Spurs Chinese Millennials to Fall For Eloquence

Retrieved on: 
Friday, March 29, 2019
Entertainment, TV and Radio, Other Entertainment, General Entertainment, Organ systems, Debate, Tongue, China, Countries, Anatomy

One of Chinas most popular television shows Super Tongue, provided by Ifeng.com (NYSE: FENG) and Shenzhen TV, tests the frontiers of professional debate and public interest.

Key Points: 
  • One of Chinas most popular television shows Super Tongue, provided by Ifeng.com (NYSE: FENG) and Shenzhen TV, tests the frontiers of professional debate and public interest.
  • As the only debater without a Chinese root, Italian boy Mattia Romeo has impressed the audience with his verbal proficiency.
  • During each debate, they argued about a topic that addresses certain social conflicts and answers Chinese youths anxiety.
  • Super Tongue, catching up with the debating spirit, has been trying to achieve a more serious and international model.

Worldwide Diabetes Device Intelligence Center 2012-2023: 13 Years of Comparable Data, with 5-Year Forecasts including Values, Volume Sales, and Price & Price Per-Capita Expenditure

Retrieved on: 
Thursday, March 28, 2019
Diabetes, Organ systems, Endocrine system, Endocrine diseases, RTT, Diabetes mellitus type 1, Diabetes mellitus, Diabetes management, Epidemiology of diabetes mellitus

The Diabetes Device market is expected to grow because of the rising diabetic population levels and increasing diabetes expenditure in established and emerging countries.

Key Points: 
  • The Diabetes Device market is expected to grow because of the rising diabetic population levels and increasing diabetes expenditure in established and emerging countries.
  • The Type 1 diabetes population completely depend on insulin therapy, and therefore, they constantly need to monitor their blood glucose.
  • Global Rise in Diabetic Population Levels:
    There has been a tremendous increase in the global diabetic population levels over the past decade.
  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.